ARTV — Artiva Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817241 ·
Last close
$10.10
Market Cap
$490.74M
52W High
$13.00
52W Low
$6.59
ADV30
494,857
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,430,000 | -23,516,000 | 105,955,000 | 20,955,000 | 18,108,000 |
| Dec 2025 | 0 | — | -21,932,000 | -20,772,000 | 130,940,000 | 26,701,000 | 20,970,000 |
| Sep 2025 | 0 | — | -22,897,000 | -21,528,000 | 148,862,000 | 25,508,000 | 19,638,000 |
| Jun 2025 | 0 | — | -22,810,000 | -21,254,000 | 169,391,000 | 28,468,000 | 20,350,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-76,751,000
Investing CF
$63,411,000
Financing CF
$9,000
CapEx
$-2,587,000
Dividends Paid
—
Buybacks
$-4,183,000
EPS Diluted TTM
$-3.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-330,549,000
Inventory
—
Receivables
$67,000
ST Investments
$81,307,000
EBIT TTM
$-89,810,000
Pretax Income TTM
$-83,865,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -89,810,000 | -83,865,000 | 130,940,000 | 20,970,000 | — | -76,751,000 |
| Dec 2024 | 251,000 | -67,282,000 | -58,179,000 | 209,581,000 | 22,940,000 | — | -55,032,000 |
| Dec 2023 | 33,492,000 | -30,671,000 | -32,766,000 | 105,114,000 | 267,129,000 | — | -47,430,000 |
| Dec 2022 | 4,931,000 | -59,829,000 | -60,976,000 | 133,054,000 | 273,750,000 | — | -50,829,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | $498.62M | $9.21 | — |
| VALN | Valneva SE | $507.53M | $4.97 | — |
| ZURA | Zura Bio Ltd | $515.20M | $5.43 | — |
| PRME | Prime Medicine, Inc. | $527.40M | $2.92 | — |
| TECX | Tectonic Therapeutic, Inc. | $528.90M | $28.03 | — |
News headlines (Yahoo Finance, 1h cache)
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 11:30 · Yahoo
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
2026-07-08 13:40 · Yahoo
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-23 20:05 · Yahoo
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
2026-06-08 10:30 · Yahoo
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cel
2026-05-19 20:05 · Yahoo
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
2026-05-19 12:00 · Yahoo
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-05-08 10:52 · Yahoo
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-08 10:31 · Yahoo
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
2026-05-08 10:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-07-31 17:13:03 | 2026-07-29 | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | 9.96 | 45768 | 455726 |
| 2026-07-28 17:24:04 | 2026-07-24 | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | 9.99 | 41319 | 412777 |
| 2026-07-23 21:22:32 | 2026-07-21 | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | 9.76 | 264586 | 2583314 |